JP2018522053A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522053A5
JP2018522053A5 JP2018506137A JP2018506137A JP2018522053A5 JP 2018522053 A5 JP2018522053 A5 JP 2018522053A5 JP 2018506137 A JP2018506137 A JP 2018506137A JP 2018506137 A JP2018506137 A JP 2018506137A JP 2018522053 A5 JP2018522053 A5 JP 2018522053A5
Authority
JP
Japan
Prior art keywords
combination
composition
tlr4 agonist
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522053A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/053290 external-priority patent/WO2017021792A1/en
Publication of JP2018522053A publication Critical patent/JP2018522053A/ja
Publication of JP2018522053A5 publication Critical patent/JP2018522053A5/ja
Pending legal-status Critical Current

Links

JP2018506137A 2015-08-06 2016-06-03 Tlr4アゴニストおよびその組成物ならびに癌の処置におけるそれらの使用 Pending JP2018522053A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201912P 2015-08-06 2015-08-06
US62/201,912 2015-08-06
PCT/IB2016/053290 WO2017021792A1 (en) 2015-08-06 2016-06-03 Tlr4 agonists and compositions thereof and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2018522053A JP2018522053A (ja) 2018-08-09
JP2018522053A5 true JP2018522053A5 (https=) 2019-07-04

Family

ID=56121139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506137A Pending JP2018522053A (ja) 2015-08-06 2016-06-03 Tlr4アゴニストおよびその組成物ならびに癌の処置におけるそれらの使用

Country Status (10)

Country Link
US (1) US10765690B2 (https=)
EP (1) EP3331565A1 (https=)
JP (1) JP2018522053A (https=)
KR (1) KR20180032642A (https=)
CN (1) CN108136024A (https=)
AU (1) AU2016303387B2 (https=)
BR (1) BR112018002520A2 (https=)
CA (1) CA2994790A1 (https=)
RU (1) RU2018107930A (https=)
WO (1) WO2017021792A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
ES2985591T3 (es) 2018-02-12 2024-11-06 Inimmune Corp Ligandos de receptores tipo Toll
WO2020007760A1 (en) * 2018-07-03 2020-01-09 Glaxosmithkline Intellectual Property Development Limited Tlr4 compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions or formulations, methods of preparation, treatment or uses
WO2020031087A1 (en) * 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
KR20230106604A (ko) * 2020-11-11 2023-07-13 다이이찌 산쿄 가부시키가이샤 신규 아미노알킬글루코사미니드 4-인산 유도체
CN118453877A (zh) * 2023-08-04 2024-08-09 中国人民解放军海军军医大学 小分子化合物组合在制备启动肝脏原位再生药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP2000144A1 (en) 2000-05-19 2008-12-10 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
US7129219B2 (en) 2000-08-04 2006-10-31 Corixa Corporation Immunoeffector compounds
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CA2748038A1 (en) * 2008-12-23 2010-07-01 Glaxosmithkline Biologicals S.A. Method for inducing a trif-bias
WO2010089411A2 (en) * 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
AU2011258165B2 (en) * 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EP2986303B1 (en) * 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment

Similar Documents

Publication Publication Date Title
JP2018522053A5 (https=)
Rauch et al. Survivin and YM155: how faithful is the liaison?
JP2019521180A5 (https=)
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
JP2013503174A5 (https=)
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
NZ739902A (en) Multiligand agent for drug delivery
WO2016080810A3 (ko) 바이구아나이드 화합물 및 이의 용도
GEP20237470B (en) Magl inhibitors
EP4011871A3 (en) Processes for preparing oxathiazin-like compounds
EA201370103A1 (ru) Соединения и композиции для лечения рака
HRP20150530T1 (hr) Spojevi korisni za inhibiranje chk1
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
JP2013541586A5 (https=)
GEAP202115310A (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND THEIR USE
WO2016130581A8 (en) Combination cancer therapy
RU2019105574A (ru) Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
WO2015193517A3 (en) Liquid pharmaceutical composition comprising pemetrexed
CO6341557A2 (es) Derivados nitrogenados de la pancratistatina